The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.00 (0.00%)
Spread: 0.70 (7.955%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.15
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Tue, 28th Apr 2020 14:43

(Alliance News) - The follow is a round-up of share dealings by London-listed company directors and managers announced on Monday and Tuesday and not separately reported by Alliance News:

----------

easyHotel PLC - Citrus Holdco Ltd, the investment vehicle of Chair Hermanus Meijer, Non-Executive Director Charles Persello, and Michael Neuman, representative of corporate director Cadim Fonds Inc, buys 183,688 shares at GBP0.70, worth GBP128,582, on Friday last week. At the start of last week, easyHotel offered an exit opportunity to minority shareholders at the same price. Citrus Holdco held 71.2% of the shares at that point, with brand-owner easyGroup having 25.8%, leaving just 3% in public hands. easyHotel plans to cancel its listing on AIM from May 19.

----------

Witan Investment Trust PLC - Non-Executive Director Gabrielle Boyle buys 28,683 shares at 173.41p, worth GBP49,739, on Monday.

----------

Scancell Holdings PLC - Non-Executive Director Martin Diggle sells 2.0 million shares via Vulpes Life Science Fund, at 8p, worth GBP160,000, on Monday and Friday last week. Vulpes now holds 78.5 million shares, a 17% stake.

----------

Manchester & London Investment Trust PLC - Investment Manager Mark Sheppard sells 58,266 shares at GBP5.62 and GBP5.66, worth GBP327,586, on Monday.

----------

Geiger Counter Ltd - Chair George Baird buys 100,000 shares at GBP0.17, worth GBP16,680, on Friday last week.

----------

Alfa Financial Software Holdings PLC - Chief Financial Officer Duncan Magrath buys 100,000 shares at GBP0.79, worth GBP79,000, on Monday.

----------

Artemis Alpha Trust PLC - Fund Manager Kartik Kumar buys 12,500 shares at GBP2.45, worth GBP30,625, on Friday last week.

----------

Jadestone Energy Inc - Non-Executive Chair Dennis McShane buys 150,732 shares at 43.02p to 44.40p, worth GBP65,337, on Friday last week and Monday. Now holds 453,651 shares.

----------

Salt Lake Potash Ltd - Chair Ian Middlemas buys 2.3 million shares, CEO Tony Swiericzuk 505,883, and CFO Shaun Day 102,941 last week, as part of company's placement of 58.8 million shares at AUD0.34 to raise AUD20.0 million. The funds will be used to deliver the Lake Way project in Western Australia. Salt Lake Potash said commissioning is expected to commence in December with first production in the first quarter of 2021.

----------

City Merchants High Yield Trust Ltd - Non-executive directors Tim Scholefield and Stuart McMaster buy 6,000 shares at 171.80p and 25,000 shares at 171.67p, respectively, on Tuesday. The purchases are together worth GBP53,000.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.